BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38554442)

  • 1. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
    Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
    Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Withanolides from
    Huang L; Wei Y; Ni M; Hu H; Xi L; Wang C; Zhu Z; Yang B; Zhao H
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
    Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
    J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis.
    Yang X; Liang B; Zhang L; Zhang M; Ma M; Qing L; Yang H; Huang G; Zhao J
    Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38847277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
    Yu X; He Z; Wang Z; Ke S; Wang H; Wang Q; Li S
    Exp Cell Res; 2024 May; 438(2):114053. PubMed ID: 38663476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. POU2F2-mediated upregulation of lncRNA
    Li J; Li PT; Wu W; Ding BN; Wen YG; Cai HL; Liu SX; Hong T; Zhang JF; Zhou JD; Qian LY; Du J
    Epigenomics; 2024 Feb; 16(4):215-231. PubMed ID: 38318853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
    Du J; Wang L; Huang X; Zhang N; Long Z; Yang Y; Zhong F; Zheng B; Lan W; Lin W; Ma W
    Phytomedicine; 2021 May; 85():153551. PubMed ID: 33827043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
    Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
    Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
    Emad B; WalyEldeen AA; Hassan H; Sharaky M; Abdelhamid IA; Ibrahim SA; Mohamed HR
    BMC Cancer; 2023 Nov; 23(1):1151. PubMed ID: 38012585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
    Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
    J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy inhibits cancer progression and induces ferroptosis and apoptosis by targeting P53/GPX4/SLC7A11 signaling pathways in cholangiocarcinoma.
    Yan X; Li Z; Chen H; Yang F; Tian Q; Zhang Y
    Photodiagnosis Photodyn Ther; 2024 Jun; 47():104104. PubMed ID: 38679154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer.
    Zhang Z; Lu M; Chen C; Tong X; Li Y; Yang K; Lv H; Xu J; Qin L
    Theranostics; 2021; 11(7):3167-3182. PubMed ID: 33537080
    [No Abstract]   [Full Text] [Related]  

  • 13. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
    Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
    Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis.
    Song X; Wang X; Chen X; Yu Z; Zhou Y
    J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.
    Lou JS; Zhao LP; Huang ZH; Chen XY; Xu JT; Tai WC; Tsim KWK; Chen YT; Xie T
    Phytomedicine; 2021 Jan; 80():153370. PubMed ID: 33113504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
    Wang L; Chen Y; Mi Y; Qiao J; Jin H; Li J; Lu Z; Wang Q; Zou Z
    Biochem Biophys Res Commun; 2021 Jun; 558():216-223. PubMed ID: 33008584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer.
    Yang J; Zhou Y; Xie S; Wang J; Li Z; Chen L; Mao M; Chen C; Huang A; Chen Y; Zhang X; Khan NUH; Wang L; Zhou J
    J Exp Clin Cancer Res; 2021 Jun; 40(1):206. PubMed ID: 34162423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.